Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug resistant Plasmodium falciparum isolates from Cambodia

21 Jul 2014

Charlotte A. Lanteri, Suwanna Chaorattanakawee, Chanthap Lon, David L. Saunders, Wiriya Rutvisuttinunt, Kritsanai Yingyuen, Ian Bathurst, Xavier C. Ding, Stuart D. Tyner

Antimicrobial Agents and Chemotherapy

DOI:

Abstract

Novel synthetic endoperoxides are being evaluated as new components of artemisinin combination therapies (ACTs) to treat artemisinin resistant Plasmodium falciparum malaria. We conducted blinded ex vivo activity testing of fully synthetic (OZ78, OZ277) and semi-synthetic endoperoxides (artemisone, artemiside, artesunate, dihydroartemisinin) in the histidine-rich protein 2 ELISA against 200 P. falciparum isolates from areas of artemisinin-resistant malaria in western and northern Cambodia in 2009/10. Geomean (GM) IC50s were: artemisone (2.40 nM) > artesunate (8.49 nM) > dihydroartemisinin (11.26 nM) > artemiside (15.28 nM) > OZ277 (31.25 nM) > OZ78 (755.27 nM). Ex vivo activities of test endoperoxides positively correlated with dihydroartemisinin and artesunate. The isolates were over 2-fold less susceptible to dihydroartemisinin relative to the artemisinin-sensitive P. falciparum W2 clone, and showed comparable sensitivity to test endoperoxides and artesunate with isolate/W2 IC50 susceptibility ratios < 2.0. All isolates had P. falciparum chloroquine resistance transporter mutations, with negative correlations in sensitivity to endoperoxides and chloroquine. Activity of endoperoxides (artesunate, dihydroartemisinin, OZ277, artemisone) significantly correlated with that of the ACT partner drug, mefloquine. Isolates had mutations associated with clinical resistance to mefloquine, with 35% prevalence of P. falciparum multidrug resistance gene 1 (pfmdr1) amplification and 84.5% occurrence of pfmdr1 Y184F mutation. GM IC50s for mefloquine, lumefantrine, and endoperoxides (artesunate, dihydroartemisinin, OZ277, OZ78, artemisone) correlated with pfmdr1 copy number. Given that current ACTs are failing potentially from reduced sensitivity to artemisinins and partner drugs, newly identified mutations associated with artemisinin resistance reported in the literature and pfmdr1 mutations should be examined for their combined contributions to emerging ACT resistance.

Read the full article on the Antimicrobial Agents and Chemotherapy website.